Efficacy of single-agent lenalidomide in patients with JAK2 (V617F) mutated refractory anemia with ring sideroblasts and thrombocytosis.

@article{Huls2010EfficacyOS,
  title={Efficacy of single-agent lenalidomide in patients with JAK2 (V617F) mutated refractory anemia with ring sideroblasts and thrombocytosis.},
  author={Gerwin A. Huls and Andr{\'e} B. Mulder and Stefano Rosati and Arjan A. van de Loosdrecht and Edo Vellenga and Joost T. M. de Wolf},
  journal={Blood},
  year={2010},
  volume={116 2},
  pages={180-2}
}
Patients with refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) are difficult to treat because the cytoreductive treatment might be beneficial for the thrombocytosis component but harmful for the RARS component. As lenalidomide has shown to be efficacious in both myelodysplastic syndromes and myeloproliferative neoplasms, we have treated 2 RARS-T patients, who were transfusion dependent, with lenalidomide. We report the results of lenalidomide treatment in these patients and… CONTINUE READING